A closer look at “Biopharma Split on Treasury's China Rule: Contract Manufacturing Exemption Sparks Debate |”, exactly as the source publishes it. Treasury Department's proposed rule restricting certain outbound investments to China has exposed a rift within the biopharma industry, with disagreement centered on an exemption for contract manufacturing deals. The rule, which implements an executive order targeting national security thre Biopharma Split on Treasury's China Rule: Contract Manufacturing Exemption Sparks Debate
Treasury Department's proposed rule restricting certain outbound investments to China has exposed a rift within the biopharma industry, with disagreement centered on an exemption for contract manufacturing deals. The rule, which implements an executive order targeting national security threats from China in semiconductors, quantum computing, and artificial intelligence, may also capture some biotechnology transactions. While the biotech sector is not explicitly named, the broad definition of 'covered transactions' For the complete material, the listing points back to the source inside the network.